Search Results
Your search for The A,The A matches 32360 pages
Showing 23001 - 23050Expert Point of View: Sergio A. Giralt, MD
Sergio A. Giralt, MD, Chief of the Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center, New York, told The ASCO Post that defibrotide could be helpful in high-risk patients and applauded the investigators for completing the trial to prove it. “Veno-occlusive...
Defibrotide Under Review for Transplant-Related Complication
A potentially fatal complication of hematopoietic stem cell transplantation may be reversed with the use of a novel drug currently under priority review at the U.S. Food and Drug Administration (FDA). Hepatic veno-occlusive disease/sinusoidal obstruction syndrome is usually a serious complication...
How Cancer and Its Treatments Affect Cognitive Function
Although chemotherapy is often cited as the main culprit for diminishing cognitive function in patients with cancer, ushering the term “chemobrain” into the vernacular, research by Tim A. Ahles, PhD, and his colleagues is showing that multiple factors may contribute to the condition.1 Using breast...
Increased Incidence of in Situ and Invasive Melanoma in Denmark
In a study reported in JAMA Dermatology,1 Neel Maria Helvind, MD, of the University Hospital Rigshospitalet, Copenhagen, Denmark, and colleagues analyzed the increases in melanoma incidence seen in Denmark between 1985 and 2012. Over that time, the incidence of malignant melanoma doubled to rates...
Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Older Patients With AML in First Remission
In a phase II study (CALGB 100103/Alliance/Blood and Marrow Transplant Clinical Trial Network 0502) reported in the Journal of Clinical Oncology,1 Steven M. Devine, MD, of The Ohio State University, Columbus, et al found that reduced-intensity conditioning allogeneic hematopoietic stem cell...
Transcription Factor CDX2 May Be Prognostic Biomarker in Stage II and III Colon Cancer
In a study reported in The New England Journal of Medicine, Dalerba et al found that absence of the transcription factor CDX2, although prognostic for poor outcome in stage II and III colon cancer vs cancers with CDX2 expression, identified a subgroup of high-risk patients who appeared to benefit...
Increased Survival and Toxicity With Docetaxel, No Apparent Benefit of Zoledronic Acid in Prostate Cancer
As reported in The Lancet by James et al, results of the STAMPEDE trial, which used a multiarm, multistage seamless phase II/III design, showed increased survival and toxicity with docetaxel and little benefit of zoledronic acid when added to first-line long-term hormone therapy in patients with...
New Assay Detects Persistent Disease in Leukemia Patients Thought to Be in Remission
The outcomes of chronic myeloid leukemia (CML) have dramatically improved as the result of tyrosine kinase inhibitor treatment. Use of a tyrosine kinase inhibitor regimen can lower the blood CML biomarker to levels imperceptible by current detection methods. For patients in “molecular...
Bone Loss Associated With Leukemia Therapy Occurs Sooner Than Previously Thought
Investigators at Children’s Hospital Los Angeles (CHLA) have found that significant bone loss occurs during the first month of chemotherapy for acute lymphoblastic leukemia (ALL), which is far earlier than previously assumed. Results of the study were published by Orgel et al in the...
Superior Long-Term Outcomes Linked to Axillary Pathologic Complete Response After Chemotherapy for Breast Cancer
In an analysis of experience at MD Anderson Cancer Center reported in JAMA Oncology, Mougalian et al found that 10-year overall and relapse-free survival rates in patients with stage II or III breast cancer and axillary metastases receiving primary systemic chemotherapy were higher in those with vs ...
UK Trial Shows Little Benefit of Pregabalin Combined With Palliative Radiotherapy for Cancer-Induced Bone Pain
In a UK study reported in the Journal of Clinical Oncology, Fallon et al found no improvement with pregabalin vs placebo combined with concurrent palliative radiotherapy in relieving cancer-induced bone pain. Study Details In the double-blind trial, 233 patients with bone metastases who were...
World Cancer Day 2016: We Can. I Can.
Cancer will kill more than 8 million people worldwide this year, which is equivalent to the entire population of New York. Half of these will be people of working age (30–69 years old). It has been estimated that the cost implications on world economies caused by cancer and the other...
APOS Launches Psychosocial Oncology Institute
The American Psychosocial Oncology Society (APOS) will launch the inaugural Psychosocial Oncology Institute on March 3, 2016, at the Sheraton San Diego Hotel & Marina in San Diego, California. Instructors for the full-day, interactive institute—leaders in the psychosocial oncology field—will...
For Postmenopausal Women With Ductal Carcinoma in Situ: NSABP B-35 and IBIS-II DCIS Trials Offer a Choice of Endocrine Therapy
The past year has produced an embarrassment of riches regarding the value of aromatase inhibitors for women with ductal carcinoma in situ of the breast. The long-awaited NSABP B-35 study matured and was reported by Margolese and colleagues at the 2015 ASCO Annual Meeting this past summer, followed...
Comparing Recurrence Risk With Anastrozole vs Tamoxifen in Postmenopausal Women With Ductal Carcinoma in Situ
Two recently reported phase III trials compared adjuvant anastrozole vs tamoxifen in postmenopausal women with hormone receptor–positive ductal carcinoma in situ. As reported in The Lancet by Margolese et al,1 the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-35 trial, performed in...
Dose-Intensified vs Standard Salvage Radiation for Biochemically Recurrent Prostate Cancer After Prostatectomy
Initial results of a European phase III trial (SAKK 09/10), reported in the Journal of Clinical Oncology by Ghadjar et al of the Swiss Group for Clinical Cancer Research, showed little difference in acute toxicity with salvage radiotherapy of 70 vs 64 Gy in patients with biochemical recurrence of...
Dutch Trial Indicates 6-Year Surveillance Interval Is Sufficient for Many Individuals With Familial Colorectal Cancer
In a Dutch trial reported in the Journal of Clinical Oncology, Simone D. Hennink, MD, of Leiden University Medical Center in Leiden, the Netherlands, and colleagues found that a 6-year colonoscopic surveillance interval is sufficient for many individuals with familial colorectal cancer.1 However,...
ASCO Comments With Fellow Leading Medical Organizations on Proposed Changes to Common Rule
On January 4, ASCO submitted a joint comment letter with the American Association for Cancer Research (AACR), Association of American Cancer Institutes (AACI), and American Society of Radiation Oncology (ASTRO) to the U.S. Department of Health and Human Services on proposed changes to the Common...
ASCO Names Advance of the Year, Highlights Major Top Research Trends
Research is the bedrock of progress against cancer, and discoveries in cancer biology are moving from bench to bedside faster than ever. No recent advance has been more transformative than the rise of immunotherapy, particularly over the past year, making this treatment strategy ASCO’s Advance of...
Stavros Niarchos Foundation Grant Brings Quality Improvement Program to Practices Supporting Medically Underserved Communities
The Conquer Cancer Foundation of ASCO has received a generous grant from the Stavros Niarchos Foundation (SNF) in support of a new ASCO initiative, “Improving the Delivery of Cancer Care in Medically Underserved Communities.” Over an 18-month period, this initiative will bring ASCO’s Quality...
Researcher Spotlight: Conquering Cancer With Dr. Wagle
When it comes to cancer, one of the most frustrating moments for patients and doctors alike is discovering a promising treatment has suddenly stopped working. Generally, this occurs when cancer develops resistance and finds ways to bypass a treatment’s effects. Cancer drug resistance happens more...
Neoadjuvant HER2 Inhibitor Therapy and Effect of Molecular Heterogeneity on Response in HER2-Positive Breast Cancer
In the phase III CALGB 40601 trial, reported in the Journal of Clinical Oncology by Lisa A. Carey, MD, of University of North Carolina at Chapel Hill, and colleagues, pathologic complete response rate was not significantly increased by adding neoadjuvant trastuzumab (Herceptin) plus lapatinib...
ASCO Names Cancer Advance of the Year: Immunotherapy
At a Capitol Hill briefing today, ASCO announced immunotherapy as the top cancer advance of the year. Recent breakthroughs in immunotherapy—along with almost 60 other important cancer research advances—are described in ASCO's just-released report, Clinical Cancer Advances 2016: ASCO's...
American College of Physicians Issues Advice, Raises Questions About Best Practices for Hematuria as a Sign of Cancer
In some patients, blood in the urine, or hematuria, may be the only warning sign of cancer in the urinary tract. A new report from the American College of Physicians’ (ACP) High Value Care Task Force published by Nielsen et al in Annals of Internal Medicine issues advice for physicians on how ...
High Rate of Local Control Reported With High-Dose Hypofractionated Proton Beam Therapy in Liver Cancers
High-dose hypofractionated proton beam therapy produced a high rate of local control in patients with localized unresectable hepatocellular carcinoma or intrahepatic cholangiocarcinoma, according to a phase II study reported in the Journal of Clinical Oncology by Hong et al. Study Details In the...
Expert Point of View: C. Kent Osborne, MD
These data will help us personalize treatment for our patients. We still don’t know which women with a favorable cancer like ductal carcinoma in situ are most likely to progress. This is an unmet need,” said C. Kent Osborne, MD, Director of the Dan L. Duncan Cancer Center at Baylor College of...
Tamoxifen or Anastrozole for Ductal Carcinoma in Situ?
Ductal carcinoma in situ is a relatively benign form of breast cancer (stage 0), yet up to 10% of women with ductal carcinoma in situ will have a recurrence within 10 years. At present, there is no way to identify which women will recur, so standard treatment is lumpectomy plus radiation therapy....
Expert Point of View: Emily Sedgwick, MD
Emily Sedgwick, MD, Associate Professor of Radiology at Baylor College of Medicine, Houston, indicated that the study by Holt et al is the first description of the synthetic two-dimensional (2D) screening approach and has the strength of being prospective in design. Future evaluations would benefit ...
Synthetic 2D Mammography May Hold Advantages Over 2D/3D Mammography
In screening for breast cancer, results from a study in the United Kingdom suggest that the use of “synthetic” two-dimensional (2D) mammography, rather than 2D/three-dimensional (3D) combinations, could save radiologists’ time and patients’ exposure to radiation as well as result in many fewer...
Dr. Abraham’s Top-10 Picks for the Most Clinically Relevant Breast Cancer Studies of 2015
Sparano JA, Gray RJ, Makower DF, et al: Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 373:2005-2014, 2015. Chagpar AB, Killelea BK, Tsangaris TN, et al: A randomized, controlled trial of cavity shave margins in breast cancer. N Engl J Med 373:503-510, 2015....
Selected Abstracts From 2015 San Antonio Breast Cancer Symposium
The 2015 San Antonio Breast Cancer Symposium (SABCS), hosted by the American Association for Cancer Research, the Cancer Therapy & Research Center at The University of Texas Health Sciences Center at San Antonio, and Baylor College of Medicine, was held in December 2015. As has been true for...
Expert Point of View: Suleiman Massarweh, MD
Suleiman Massarweh, MD, Associate Professor of Medicine at Stanford University School of Medicine, Palo Alto, and Director of Breast Clinical Trials at Stanford Cancer Institute, commented on the ADAPT trial for The ASCO Post. “The complete pathologic response rate in estrogen...
High Pathologic Complete Response Rates Observed With Neoadjuvant Ado-Trastuzumab Emtansine
Neoadjuvant treatment with a chemotherapy-free, anti-HER2 regimen yielded high rates of pathologic complete response in patients with HER2-positive, hormone receptor-positive early breast cancer in the phase II WSG-ADAPT HER2+/HR+ (ADAPT) trial presented at the 2015 San Antonio Breast Cancer...
Expert Point of View: Thierry Facon, MD
Several experts commented that an all-oral regimen would bring convenience to the treatment of myeloma. Thierry Facon, MD, of Lille University Hospital in France, told The ASCO Post that although ixazomib (Ninlaro) may not be more active than other proteasome inhibitors, “It definitely has...
Studies Confirm and Extend the Benefits of Ixazomib in Multiple Myeloma
Patients with multiple myeloma now have access to an all-oral regimen, with the recent approval of the oral proteasome inhibitor ixazomib (Ninlaro) in previously treated patients. New pairings for the drug in relapsed/refractory and newly diagnosed patients are being studied, with investigators...
New Appointments Within FDA’s Office of Hematology and Oncology Products
The U.S. Food and Drug Administration (FDA) recently announced the appointment of an Acting Deputy Office Director and an Associate Director of Clinical Science in its Office of Hematology and Oncology Products (OHOP). Acting Deputy Office Director Amy E. McKee, MD, was recently announced as the...
Pembrolizumab Label Updated With New Clinical Trial Information
Late in 2015, the U. S. Food and Drug Administration (FDA) expanded the label for pembrolizumab (Keytruda), a humanized antibody, to include the initial treatment of patients with unresectable or metastatic melanoma. Previously, pembrolizumab had received accelerated approval in patients with...
Expert Point of View: Sumanta K. Pal, MD
Commenting on both the CheckMate 025 and METEOR studies, Sumanta K. Pal, MD, Co-Director of the Kidney Cancer Program at City of Hope Comprehensive Cancer Center, Duarte, California, said, “Cabozantinib (Cometriq) will probably be approved for advanced renal cell carcinoma. There is debate about...
Expert Point of View: William Y. Kim, MD
Formal discussant of this trial William Y. Kim, MD, of the University of North Carolina’s Lineberger Comprehensive Cancer Center, Chapel Hill, commented on the fact that the IMvigor study had a substantial number of patients compared with other phase II trials in bladder cancer. “This trial was not ...
Atezolizumab in Urothelial Cancer: Ushering in a New Standard of Care
Atezolizumab achieved excellent results in a cohort of patients with platinum-resistant urothelial cancer enrolled in a large phase II trial known as IMvigor 210.1 Overall response rates were greatly improved over those with historical controls, and responses were durable. Although expression of...
Expert Point of View: Christian K. Kollmannsberger, MD
Commenting on both of these studies, Christian K. Kollmannsberger, MD, of the British Columbia Cancer Center, Vancouver, Canada, said: “These studies suggest a more personalized approach to testicular cancer. Clearly, we need to do better than traditional risk factors used to guide therapy for...
Improved Outcomes in Patients With Germ Cell Testicular Tumors in the Modern Era
Although patients with poor-risk metastatic testicular germ cell tumors continue to have less favorable outcomes, the bar has been raised by contemporary treatment. There is still room for improvement in managing metastatic testicular germ cell tumors, especially in poor-risk patients, but if...
Cancer Registries and the Evolving Role of Big Data in Cancer Care
In 1956, the American College of Surgeons encouraged the development of hospital-based registries, but for the most part, these efforts were clumsy, inaccessible card files of data. Today, advanced microcomputer technology has increased the ability to not only collect and cull cancer data but also...
'Doctor, We Prayed for You'
A 70-year-old female patient underwent a cardiac procedure to repair her mitral valve, and at the same time, she also underwent a coronary artery bypass grafting. She had an uneventful course for the first four postoperative days. On the sixth postoperative day, she started complaining of abdominal ...
Two Contenders for Second-Line Treatment of Advanced Renal Cell Carcinoma
Options for second-line therapy of advanced/metastatic renal cell carcinoma are expanding. Updates from the CheckMate 025 and METEOR trials presented at the 2016 Genitourinary Cancers Symposium solidify the value of both nivolumab (Opdivo, an immune checkpoint inhibitor) and cabozantinib...
Higher Risk of Cancer Mortality in Solid-Organ Transplant Recipients
In a study reported in JAMA Oncology, Acuna et al found a nearly threefold increased risk of cancer mortality in solid-organ transplant recipients compared with the general population in Ontario, Canada. Study Details The population-based cohort study included data from 11,061 patients who...
Study Finds Association Between Androgen-Deprivation Therapy in Prostate Cancer and Risk of Alzheimer’s Disease
In a retrospective analysis reported in the Journal of Clinical Oncology, Nead et al found that use of androgen-deprivation therapy in the treatment of prostate cancer was associated with an increased risk of subsequent Alzheimer’s disease. Study Details In the study, a text-processing...
Sparing Ovaries and Removing Fallopian Tubes May Cut Cancer Risk, but Few Have Procedure
During hysterectomies for noncancerous conditions, removing both fallopian tubes while keeping the ovaries may help protect against ovarian cancer and preserve hormonal levels, but few women receive this surgical option, according to a new study by Yale School of Medicine researchers. Published by ...
Abnormal Fused Gene Is a Triple Threat in Driving Pediatric Brain Tumors
Oncology researchers have discovered that an abnormal fused gene that drives pediatric brain tumors poses a triple threat, operating simultaneously through three distinct biologic mechanisms—the first such example in cancer biology. The study was published by Bandopadhayay et al in Nature...
Global Perspectives on the Integration of Biosimilars Into Oncology Practice
Dr. Robert Rifkin, Medical Director of Biosimilars at US Oncology Research, moderates a roundtable discussion on Global Perspectives on the Integration of Biosimilars into Oncology Practice, held in conjunction with the 2015 American Society of Hematology Annual Meeting in Orlando, Florida....
